Drug Trial Radar · NCT01656057
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
Last checked: Nov 19, 2026Latest source record: Jul 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jul 2012
Primary completion
Oct 2013
Study completion Apr 2014
Sponsor
- Lead sponsor
- Filip Krag KnopAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Copenhagen
- First posted
- Aug 2, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but also modulates the energy expenditure in (brown) adipose tissue and muscle tissue. This action is due to stimulation of the receptor TGR5 by bile acids. Recently scientists have discovered that this receptor in rodents is also expressed on the surface of intestinal L-cells (which normally secrets Glucagon-Like Peptide-1 (GLP-1) in response to nutrient stimulation). The stimulation of this receptor has shown a GLP-1 secretion from the intestinal cells which is interesting since GLP-1 has a central role in maintaining normal glucose tolerance and thus blood sugar. Given the above, bile acids has an important impact on intestinal GLP-1 secretion. Whether these scientific findings can be proven in human beings is uncertain. The primary hypothesis is that stimulating gall bladder emptying via Cholecystokinin (CCK) in healthy subjects will result in a significant GLP-1 response. We also hypothesize that adding orally Metformin or a sequestrant ("a bile acid binder") will further enhance this GLP-1 response.
Conditions
- To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
Interventions
AcetaminophenDrug
Acetaminophen dissolved in 50 ml of water
MetforminDrug
Metformin + acetaminophen dissolved in 50 ml of water
ColesevelamDrug
Colesevelam + acetaminophen dissolved in 50 ml of water
Cholecystokinin-8Other
iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
SalineOther
iv. saline infusion 40 ml/hour for the first 60 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- GLP-1 response as incremental area under curve (iAUC)Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division
Copenhagen, Hellerup, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.